Allergan recalls some Tazorac acne gel

Allergan, which made its name with dermatology products like Botox, recalled more than 42,000 tubes of an acne gel that failed to meet specifications during stability testing.

According to the most recent FDA Enforcement Report, Allergan recalled 42,359 tubes of Tazorac in 30-g and 100-g sizes because the gel at the 24-month stability test fell slightly below regulatory specifications for product concentration and content uniformity.

In a letter to retailers, Allergan said the health risk is slight because the product is below specs and that it has not received any reports of adverse events. The voluntary recall actually began in June but was only classified last week by the FDA and posted on its site today..

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Allergan last year recalled about 50 lots of some of the eye ointments sold under the brands Refresh, Lacri-Lube and others after receiving a dozen consumer complaints of a small black particle in the product. Allergan determined that the particle was created when unscrewing the cap from the aluminum tube and in some cases getting into the ointment.

Allergan had some other recalls this year, but those were tied to the Actavis generics unit it was recently sold to Teva for $40.5 billion.

- access the recall report here
- here’s the Allergan recall letter

Related Articles:
Allergan recalls eye drugs after patients complain of particles, blurred vision
Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug

Read more on

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.